16 May 2016
A new Russian vaccine to prevent B-type hepatitis is entering the global market. According to experts, taking an injection with the new vaccine will give a person long-term confidence as it is said to stay active for many years.
“This is a unique vaccine from the standpoint of the ideology of its development. It contains no biocomponents or biological tissues of a sick person, which has been widespread in developing the prior generations of vaccines. This new vaccine is absolutely genetically engineered and based on a high-specificity virus active in the Russian Federation,” explained Igor Nikitin who heads the hospital therapy chair at the Moscow-based Pirogov Russian National Research Medical University.
The vaccine is said to have emerged a few years ago already in the labs of Kombiotech, a Moscow-based biotech company. The developer has reportedly been manufacturing an estimated five million ampoules of the vaccine a year for domestic consumption.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Health Ministry registered Russian drug for ankylosing spondylitis
06 May 2024
How gut enzymes could make universal donor blood possible
06 May 2024
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024